Stem cell studies continue to make big news with a mixed bag of trends including for stem cell biotech, and some good stem cell news and others not so much. Mesoblast ($MESO) had its stock suspended for quite so time recently in anticipation of a big announcement. When that news came today it was discouraging in […]
Stem cell biotech bites: Mesoblast, BioTime, MS, FDA Warning, & More Read More »
A sad, but not surprising day for the stem cell field as the biotech StemCells, Inc. announced that it is winding down its operations after terminating its spinal cord injury trial called the Pathway Study. The data generated so far did not justify continuing the trial. StemCells, Inc. (stock symbol STEM) has struggled financially for
End of line for StemCells Inc., pioneering & controversial stem cell biotech Read More »
To get from point A of a stem cell discovery to point B of a patient actually receiving a treatment based on that discovery is a long and non-linear road, which requires biotech company research. Stem cell biotech companies including publicly traded companies are an integral part of the field making that journey. How those
Tale of 7 stem cell biotech stock woes Read More »
What the heck is going on with Intellicell Biosystems, Inc. (SVFC, also SVFCE), a stem cell corporation run by Dr. Steven Victor? Why are some on Wall Street seeming so bullish on the company lately? What’s the real story and the facts? What is the key background on this company? Wall Street has been buying
Wall Street Weirdness Over Stem Cell Biotech Intellicell (SVFC) Read More »
What does it take to be a stem cell biotech CEO?I’ve been running a poll on what is the ideal background for the CEO of a stem cell company. We got a pretty good turnout in this poll, although one is to be reminded that Internet polls are not scientific. It’s not perfect, but the
Poll results on stem cell biotech CEO are interesting Read More »
For the second year in a row (see awards 2011), Advanced Cell Technology (ACT; stock symbol ACTC) is my stem cell biotech of the year. Their trials for different forms of macular degeneration (here and here and here) are progressing well and as a stem cell scientist I really appreciate the fact they are publishing their
Stem cell biotech of the year 2012: Advanced Cell Technology (ACTC) Read More »
Advanced Cell Technology (ACT; stock symbol ACTC) announced that it has secured $35 million in funding from investment company, Lincoln Park Capital. The press release quotes CEO Gary Rabin: “We are most pleased about this financing agreement, as it has a number of notable benefits for the company,” commented Gary Rabin, chairman and CEO of
Stem Cell Biotech Advanced Cell Technology (ACT) gets $35 million Read More »
What will we define as a success for any given stem cell biotech like ViaCyte? In academia, even if we do pre-clinical, translational kind of biomedical sciences, we still do not often think about what it takes to succeed in industry. Even if we very much want our research to make a difference for patients,
How is Geron doing along with other stem cell biotechs? What’s going on these days with biotech companies working on stem cell-based products? Geron and ACT Geron’s and Advanced Cell Technology (ACT)’s FDA-approved trials presumably continue. As expected, no news yet. It’s too soon. Two important questions regarding both these companies are (1) did they
Stem cell biotech updates: Geron, ACT, Neuralstem, Pfizer Read More »
There’s some recent stem cell good news out there including new papers and biotech developments. The stem cell and regenerative medicine field is really diverse and runs the gamut from really worrying stuff to very exciting, legit developments. In this post, I’m going to focus on the encouraging recent developments. What do I see as
Stem cell good news on biotechs & cool new organoid paper Read More »